Cases & Deals

  • Home
  • Practices
  • DNARx develops global patent portfolios for HEDGES™ gene therapy platform

Share

DNARx develops global patent portfolios for HEDGES™ gene therapy platform

November 2022

Client(s) DNARx, LLC

Jones Day represents DNARx, LLC in the development and prosecution of global patent portfolios related to HEDGES™ (High-level Extended Duration Gene Express System), DNARx's proprietary non-viral gene therapy together with gene-based, highly combinatorial anti-pandemic monoclonal antibody cDNA-encoded protein delivery platform technology for the treatment of various unmet medical needs.

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.